Skip to main content

Together we are beating cancer

Donate now

Conferences

Showing 12 out of 122 results
A group of four middle-aged adults jogging alongside a track in a park on a sunny day.

The latest research presented at ASCO shows that a tailored exercise regime can help reduce the risk of colon cancer returning after treatment. The latest research presented at ASCO shows that a tailored exercise regime can help reduce the risk of colon cancer returning after treatment.

by Amal Iman, Tim Gunn | News | 1 June 2025

1 June 2025

This entry is part 3 of 5 in the series Stand Up To Cancer
A group of killer T cells (green and red) surrounding a cancer cell (blue, center).

With the world's cancer researchers in Chicago for the 2025 American Society of Clinical Oncology (ASCO) annual meeting, we're highlighting some of the most interesting and important studies. With the world's cancer researchers in Chicago for the 2025 American Society of Clinical Oncology (ASCO) annual meeting, we're highlighting some of the most interesting and important studies.

by Tim Gunn, Amal Iman | News | 31 May 2025

31 May 2025

Lung cancer cells seen through a microscope.
  • Science & Technology
  • Health & Medicine

ASCO 2023 roundup: Blood tests, drugs and exercise

ASCO’s annual meeting is the world’s biggest cancer conference. This year’s highlights included updates on cancer blood tests, AI tools for estimating cancer risk, better drugs for some lung and ovarian cancers, and interesting data on how yoga can help patients. ASCO’s annual meeting is the world’s biggest cancer conference. This year’s highlights included updates on cancer blood tests, AI tools for estimating cancer risk, better drugs for some lung and ovarian cancers, and interesting data on how yoga can help patients.

by Tim Gunn, In collaboration with PA Media Group | News | 12 June 2023

12 June 2023

Black in Cancer co-founders Dr Henry Henderson and Sigourney Bonner on stage at the start of teh Black in Cancer conference

Many cancers affect Black people differently. Often, their outcomes are worse. There's a long way to go to change that, but this is how we can start. Many cancers affect Black people differently. Often, their outcomes are worse. There's a long way to go to change that, but this is how we can start.

by Tim Gunn | In depth | 31 October 2022

31 October 2022

Human breast cancer cells.
  • Science & Technology
  • Health & Medicine

Precision drug slows progression of advanced breast cancer

Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment. Patients taking the drug trastuzumab deruxecan were 72% less likely to see their cancer grow significantly or to die than those on an existing breast cancer treatment.

by In collaboration with PA Media Group | News | 21 September 2021

21 September 2021

Prostate cancer cells
  • Science & Technology
  • Health & Medicine

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference. Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

by Cancer Research UK | News | 19 September 2021

19 September 2021

Lung adenocarcinoma cells
  • Science & Technology
  • Health & Medicine

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented. One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

by Harry Jenkins | Analysis | 9 June 2021

9 June 2021

Photo of an elderly man holding a walking stick

Older patients with advanced oesophageal and stomach cancers might benefit from low dose treatment, according to our unpublished clinical trial results. Older patients with advanced oesophageal and stomach cancers might benefit from low dose treatment, according to our unpublished clinical trial results.

by Gabriella Beer | Analysis | 15 May 2019

15 May 2019